1. Pink Sheet
  2. >>Vaccines

Don’t Call It A Booster: Immunocompromised May Be First To Get Extra COVID Shot In US

 
• By Sarah Karlin-Smith

Reports indicate a 13 August CDC advisory committee meeting may be used to address an amended FDA emergency use authorization to allow immunosuppressed Americans to get additional COVID-19 vaccine doses. Such a move would not run afoul of the World Health Organization’s plea for a moratorium on boosters in the general population until much of the world initially can be vaccinated. 

booster vaccine dose
The US FDA is inching closer to making determinations on the need for COVID-19 booster shots. • Source: Alamy

The US Food and Drug Administration and Centers for Disease Control and Prevention are likely to soon permit the administration of an additional COVID-19 vaccine dose to immunocompromised individuals, according to recent reports, but for a variety of reasons they may steer clear of referring to the additional shots as a booster.

US media reports on 6 August indicated that the FDA could authorize the extra shots within days or weeks and that a 13 August CDC Advisory Committee on Immunization Practices meeting would address the move

More from Vaccines

Safety Review Prompts EMA to Suspend Ixchiq Chikungunya Vaccine For Seniors

 
• By Neena Brizmohun

The European Medicines Agency is investigating whether Valneva’s Ixchiq is safe to use in the elderly, following reports of 17 serious adverse events, including two cases resulting in death, in people aged 62 to 89 years who received the vaccine. This follows actions by US and French authorities last month regarding Ixchiq’s use in people over 65.

FDA Adcomms Are Back: Four Cancer Drugs, COVID-19 Vaccine Formulations To Get Reviews

 
• By Sue Sutter and Bridget Silverman

The Oncologic Drugs Advisory Committee will meet for two days in mid-May, followed by a Vaccines and Related Biological Products Advisory Committee’s review of the 2025-2026 COVID-19 vaccine formulation.

Tougher Approval Standards May Follow Vinay Prasad’s Appointment To Lead US FDA’s CBER

 
• By Sarah Karlin-Smith

Industry is concerned that Prasad may make regulatory flexibility tougher to obtain for cell and gene therapy, while vaccine and public health advocates are angry about Prasad’s criticisms of US COVID-19 policies.

Moderna Pivots To Increase Focus On Cancer Amid US Vaccine Policy Changes

 
• By Joseph Haas

During its first quarter earnings call, Moderna avoided criticizing vaccine policy changes, but de-emphasized its flu/COVID-19 vaccine for those under age 50 and prioritized cancer programs.

More from Pink Sheet

Global Pharma Guidance Tracker - April 2025

 
• By Vibha Sharma and Anabel Costa-Ferreira

Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Medicare Negotiation Does Not Violate Due Process, Appeals Court Rules, Other Suits At Risk

 
• By Cathy Kelly

Decision in AstraZeneca’s lawsuit against the Health and Human Services Department is a precedent-setting victory for the government and a blow to manufacturer efforts to block the price negotiation program.

Keep Talking: US FDA’s Beleaguered Biologics Center Remains Vital To Regenerative Medicine

 
• By Bridget Silverman

Advisory committee for Capricor’s deriamocel planned, regenerative medicine advanced therapy designations proliferate for osteoarthritis, and the ranks of dual RMAT/breakthrough therapy designation holders grow.